Stock Screener > Stock Ideas > Biotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Forecast Score | Market Cap | Price | Price Target | Upside/Downside | Consensus | Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXEL | Exelixis Inc | 89 | $6.61B | $21.31 | $30.20 | 41.72% | Buy | 5 | 26.80% | 66.00% | 40.12% | 35.27% |
| BDSI | Biodelivery Sciences International Inc | 89 | $405.76M | $4.02 | $8.00 | 99.00% | Strong Buy | 6 | 23.79% | 85.87% | 109.48% | 46.05% |
| VCEL | Vericel Corp | 89 | $1.84B | $40.41 | $37.67 | -6.79% | Strong Buy | 7 | 28.60% | 155.30% | 91.02% | 59.44% |
| HALO | Halozyme Therapeutics Inc | 89 | $5.46B | $40.41 | $42.67 | 5.59% | Strong Buy | 3 | 45.01% | 57.47% | 336.51% | 87.65% |
| GMAB | Genmab A | 67 | $19.88B | $30.92 | $39.00 | 26.13% | Buy | 5 | 37.11% | 22.47% | 4.35% | 4.04% |
| NBIX | Neurocrine Biosciences Inc | 67 | $8.69B | $92.97 | $130.18 | 40.03% | Buy | 12 | 20.84% | 12.33% | 64.91% | 42.14% |
| CARA | Cara Therapeutics Inc | 67 | $900.96M | $18.08 | $37.00 | 104.65% | Strong Buy | 2 | 11.75% | 43.73% | 38.42% | 35.28% |
| ALXN | Alexion Pharmaceuticals Inc | 56 | $32.49B | $148.46 | $154.90 | 4.34% | Buy | 12 | 7.40% | 78.67% | 23.12% | 14.88% |
| CORT | Corcept Therapeutics Inc | 56 | $2.77B | $23.86 | $23.33 | -2.19% | Buy | 3 | 15.76% | 18.00% | 45.62% | 41.76% |
| VNDA | Vanda Pharmaceuticals Inc | 56 | $956.56M | $17.49 | $14.00 | -19.95% | Hold | 1 | 12.52% | 50.76% | 26.18% | 22.25% |
| RPRX | Royalty Pharma plc | 56 | $16.43B | $42.34 | $53.00 | 25.18% | Buy | 6 | 4.03% | 36.63% | 29.88% | 8.99% |
| ABCM | Abcam plc | 44 | $4.76B | $21.13 | $22.33 | 5.69% | Hold | 3 | 14.18% | 77.30% | 18.23% | 11.29% |
| JAZZ | Jazz Pharmaceuticals plc | 44 | $8.94B | $160.45 | $185.36 | 15.53% | Buy | 11 | 11.47% | 51.34% | N/A | N/A |
| NVO | Novo Nordisk A S | 33 | $163.21B | $69.22 | N/A | N/A | Strong Buy | 1 | 5.46% | 7.31% | 88.35% | 38.61% |
| CBPO | China Biologic Products Holdings Inc | 33 | $4.60B | $118.06 | $103.00 | -12.76% | Hold | 1 | 10.61% | 17.81% | 10.04% | 8.85% |
| UTHR | UNITED THERAPEUTICS Corp | 33 | $7.13B | $160.34 | $190.80 | 19.00% | Buy | 5 | 10.43% | 9.61% | 23.29% | 17.14% |
| TECH | BIO-TECHNE Corp | 33 | $13.43B | $347.90 | $342.88 | -1.44% | Buy | 9 | 11.60% | 13.33% | 17.28% | 12.72% |
| VRTX | Vertex Pharmaceuticals Inc | 33 | $54.03B | $207.79 | $278.62 | 34.08% | Buy | 13 | 10.79% | 4.97% | 39.45% | 29.16% |
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.